Van ECK Associates Corp Acquires 3,015 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Van ECK Associates Corp boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,938 shares of the biopharmaceutical company's stock after acquiring an additional 3,015 shares during the period. Van ECK Associates Corp's holdings in Alnylam Pharmaceuticals were worth $14,808,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 143 shares during the period. Altitude Crest Partners Inc. bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at $30,000. Robeco Institutional Asset Management B.V. boosted its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 12,513 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $52,000. Finally, Benjamin F. Edwards & Company Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $71,000. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ALNY shares. Leerink Partners upped their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a "market perform" rating in a research report on Tuesday, June 25th. Barclays increased their price target on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Needham & Company LLC lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Royal Bank of Canada increased their target price on shares of Alnylam Pharmaceuticals from $265.00 to $300.00 and gave the stock an "outperform" rating in a research note on Friday, August 2nd. Finally, Raymond James lifted their price target on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. Seven research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $278.59.

Alnylam Pharmaceuticals Stock Down 8.5 %

ALNY stock traded down $24.32 during trading on Monday, reaching $262.69. The stock had a trading volume of 3,762,500 shares, compared to its average volume of 901,793. The company has a market capitalization of $33.72 billion, a price-to-earnings ratio of -98.02 and a beta of 0.37. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $287.55. The company's 50 day moving average is $256.76 and its two-hundred day moving average is $188.67.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The business's revenue was up 107.0% on a year-over-year basis. During the same period in the prior year, the company earned ($2.21) earnings per share. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares of the company's stock, valued at $18,602,548.66. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Dennis A. Ausiello sold 20,250 shares of the company's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now directly owns 136 shares in the company, valued at $35,632. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 8,301 shares of the business's stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the transaction, the chief executive officer now owns 80,534 shares of the company's stock, valued at $18,602,548.66. The disclosure for this sale can be found here. Insiders sold 103,148 shares of company stock worth $25,658,824 in the last quarter. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.